deltatrials
Completed NA NCT00034086

Study of Anti-HIV Therapy Intensification

Immunologic Consequences of Antiretroviral Therapy Intensification in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315/375

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions HIV Infections
Interventions Didanosine Haemophilus B Conjugate Vaccine Lamivudine Lamivudine/Zidovudine Lopinavir/Ritonavir Lyme Disease Vaccine Recombinant OspA Pneumococcal Vaccine, Polyvalent (23-valent) Stavudine Tenofovir disoproxil fumarate Zidovudine
Updated 6 times since 2017 Last updated: May 17, 2012 Completion: Jun 30, 2006

This NA trial investigates HIV Infections and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Jun 2018 — Jan 2021 [monthly]

    Completed NA

  5. Feb 2017 — Jun 2018 [monthly]

    Completed NA

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Aurora, United States
  • • Chicago, United States
  • • Cleveland, United States